[A summary of the experience with cisplatin in the treatment of gynecological malignancies, with special reference to advanced ovarian cancer].
This report summarizes the results on the evaluation of Cisplatin in gynecological malignancies. A total of 51 evaluable cases, comprises 29 of which were advanced or recurrent ovarian cancer and 22 of other gynecological malignancies. The main results are summarized as follow: The overall efficacy rate was 58.3% on ovarian cancer and 13.6% on other malignancies. Seen histologically, almost the same good overall efficacy rates were obtained in all types except for the mesonephroid type. When Cisplatin therapy is used in combination with surgery, the preoperative use provides a higher efficacy rate (68.2%) than the postoperative use (28.6%). Also cases with a Second Look Operation showed a much higher one year survival rate (80.0%) than those of the cases without S.L.O. (25.0%). From these results, it is deduced that Cisplatin is the most useful agent for induction chemotherapy for S.L.O. on advanced ovarian cancer. The side effects observed were milder than those of anti-cancer drugs known so far with the usual dosage, and no fetal damage was observed.
D000230:Adenocarcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D012086:Reoperation; D014839:Vomiting / Q000139:chemically induced
D002945:Cisplatin